Investors & Media

News

September 13, 2022

NGM Bio Presents Updated Preliminary Findings from the Ongoing Phase 1b Dose Escalation Trial of NGM120 in Combination with Gemcitabine and Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer at AACR Special Conference: Pancreatic Cancer

September 6, 2022

NGM Bio Presents Updated Preliminary Findings for a Subgroup of Patients with Advanced Prostate Cancer from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors at the ESMO Annual Congress

August 15, 2022

NGM Bio Announces Presentations Featuring Updated Findings from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors at the European Society of Medical Oncology (ESMO) Annual Congress and the Ongoing Phase 1b Trial of NGM120 in Patients with Advanced Pancreatic Cancer at the American Association for Cancer Research (AACR) Special Conference: Pancreatic Cancer

August 4, 2022

NGM Bio Provides Business Highlights and Reports Second Quarter 2022 Financial Results

June 30, 2022

NGM Bio Appoints Siobhan Nolan Mangini to President and Chief Financial Officer

June 23, 2022

NGM Bio to Host the Final of Four Virtual R&D Events on June 29, 2022

June 2, 2022

NGM Bio to Participate in Upcoming Investor Conferences

May 24, 2022

NGM Bio to Host the Third of Four Virtual R&D Events on May 31, 2022

May 12, 2022

NGM Bio Announces Initiation of Phase 1/1b Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors

May 5, 2022

NGM Bio Provides Business Highlights and Reports First Quarter 2022 Financial Results

Displaying 1 - 10 of 22

Contact Information

investor relations

ir@ngmbio.com

media relations

media@ngmbio.com